Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

18:38:11 Europe / Stockholm

Svenska | English

BioStock

BioInvent International AB: BioStock: Top oncologist underscores BioInvent's potential for "Immunotherapy 2.0"

2024-07-01 08:15:00

BioInvent recently announced promising clinical data for its lead cancer immunotherapy candidates, BI-1808 and BI-1206. The company hosted a Key Opinion Leader webinar to explain the results in detail, featuring insights from internationally recognized oncologist Dr Alexander Eggermont. According to Dr Eggermont, BioInvent's candidates hold great promise for the future of immuno-oncology.

Read the article at biostock.se:

Top oncologist underscores BioInvent's potential for "Immunotherapy 2.0" - BioStock (https://www.biostock.se/en/2024/07/kol-lyfter-fram-bioinvents-potential-inom-immunterapi-2-0/)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden